IP Library Granted Patent US 12,115,037
Granted Patent B2
US 12,115,037 · App. 16/490,147 · Granted Oct 15, 2024

Systems and methods of assisted reproduction and prevention of genetic defects in offspring using induced pluripotent stem cells

Inventors: Robin Y. Smith (Boston, MA); Marcie A. Glicksman (Boston, MA)
Assignee: Sapphiros AI Bio LLC
A61D19/04A61B17/435C12N5/061C12N5/0611C12N9/22C12N15/11C12N15/907C12N2310/20C12N2506/45C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,115,037
App. No.
16/490,147
Granted
Oct 15, 2024
Kind
B2
Abstract

Reserves of immortalized genetic material are stored in a bank for providing a resource (e.g., artificial gametes) for couples (e.g., same sex couples) to produce biologically-related children. The reserves provide the ability to derive sperm from induced pluripotent stem cells (iPSCs) of one partner and/or eggs from iPSCs of the other partner. For example, a biological sample is stored as iPSCs that can be used to generate an unlimited supply of genetic material (e.g., artificial gametes for conception) when needed by a user (e.g., a year or more after the sample is provided, e.g., 5 years or more after the sample is provided). Such a bank is helpful for an individual in a same sex (or infertile) couple who desires to have biological children at some point during his/her lifetime, but does not plan to have children in the immediate timeframe, for example.

Claims (28)

1. A method for assisted reproduction using induced pluripotent stem cells (iPSCs), the method comprising the steps of:

accessing, from a physical repository, one or more iPSCs derived from one or more cells of a first subject collected from a first biological sample obtained from the first subject;

making one or more egg cells from the one or more accessed iPSCs; and

contacting the one or more egg cells and one or more sperm cells to facilitate fertilization of the one or more egg cells;

wherein the step of making the one or more egg cells from the one or more iPSCs comprises genetically modifying the one or more iPSCs of the first subject using a genome editing technique to remove, replace, and/or edit one or more genes that cause(s) or is/are known to increase risk of a disease or condition in the subject(s) or a potential offspring of the subject(s).

2. The method of claim 1 , wherein the one or more sperm cells are derived from one or more iPSCs derived from one or more cells collected from a second biological sample obtained from a second subject.

3. The method of claim 1 , wherein the first subject is male.

4. The method of claim 1 , wherein the step of making the one or more egg cells from the one or more iPSCs comprises differentiating the one or more iPSCs into one or more primordial germ cells, implanting the one or more primordial germ cells into an ovary to allow gametogenesis to transform the one or more germ cells into one or more egg cells, and retrieving the one or more egg cells for in vitro fertilization with the one or more sperm cells.

5. The method of claim 1 , wherein the disease or condition comprises a member selected from the group consisting of cystic fibrosis, Huntington's disease, cancer, sickle-cell disease, Down syndrome, Prader-Willi syndrome, muscular dystrophy, neurofibromatosis, phenylketonuria, Angelman syndrome, haemophilia, haemochromatosis, polycystic kidney disease, spinal muscular atrophy, Tay-Sachs disease, and Turner syndrome.

6. The method of claim 1 , wherein the first biological sample comprises a member selected from the group consisting of blood, plasma, skin, saliva, and hair.

7. The method of claim 1 , further comprising:

selecting, from the one or more contacted egg cells, one or more fertilized egg cells; and

genetically modifying the one or more fertilized egg cells using a genome editing technique to remove, replace, and/or edit one or more genes that cause(s) or is/are known to increase the risk of a disease or condition in the subject or an offspring of the subject.

8. The method of claim 1 , further comprising each of one or more of (i), (ii), and (iii) as follows, over a period of time: (i) accessing the iPSCs from the physical repository, (ii) maintaining the iPSCs in the physical repository, and (iii) screening the iPSCs accessed from the physical repository.

9. A method for assisted reproduction using induced pluripotent stem cells (iPSCs), the method comprising the steps of:

accessing, from a physical repository, one or more iPSCs derived from one or more cell of a first subject collected from a first biological sample obtained from the first subject;

making one or more sperm cells from the one or more accessed iPSCs; and

contacting the one or more sperm cells and one or more egg cells to facilitate fertilization of the one or more egg cells;

wherein the step of making the one or more sperm cells from the one or more iPSCs comprises genetically modifying the one or more iPSCs of the first subject or the second subject using a genome editing technique to remove, replace, and/or edit one or more genes that cause(s) or is/are known to increase risk of a disease or condition in the subject(s) or a potential offspring of the subject(s).

10. The method of claim 9 , wherein the one or more egg cells are derived from one or more iPSCs derived from one or more cells collected from a second biological sample obtained from a second subject.

11. The method of claim 9 , wherein the first subject is female.

12. The method of claim 9 , wherein the step of making the one or more sperm cells from the one or more iPSCs comprises differentiating the one or more iPSCs into one or more primordial germ cells, implanting the one or more primordial germ cells into a testis to allow gametogenesis to transform the one or more germ cells into one or more sperm cells, and retrieving the one or more sperm cells for in vitro fertilization of the one or more egg cells.

13. The method of claim 9 , wherein the disease or condition comprises a member selected from the group consisting of cystic fibrosis, Huntington's disease, cancer, sickle-cell disease, Down syndrome, Prader-Willi syndrome, muscular dystrophy, neurofibromatosis, phenylketonuria, Angelman syndrome, haemophilia, haemochromatosis, polycystic kidney disease, spinal muscular atrophy, Tay-Sachs disease, and Turner syndrome.

14. The method of claim 9 , wherein the first biological sample comprises a member selected from the group consisting of blood, plasma, skin, saliva, and hair.

15. The method of claim 9 , further comprising:

selecting, from the one or more contacted egg cells, one or more fertilized egg cells; and

genetically modifying the one or more fertilized egg cells using a genome editing technique to remove, replace, and/or edit one or more genes that cause(s) or is/are known to increase the risk of a disease or condition in the subject or an offspring of the subject.

16. The method of claim 9 , further comprising each of one or more of (i), (ii), and (iii) as follows, over a period of time: (i) accessing the iPSCs from the physical repository, (ii) maintaining the iPSCs in the physical repository, and (iii) screening the iPSCs accessed from the physical repository.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2026
From: SAPPHIROS AI BIO LLC
To: WONDERLAB HOLDINGS, INC.
Reel/Frame 073660/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2023
From: SMITH, ROBIN Y.; GLICKSMAN, MARCIE A.
To: ORIG3N, INC.
Reel/Frame 062626/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2023
From: SEAPORT DIAGNOSTICS, INC.
To: SAPPHIROS AI BIO LLC
Reel/Frame 062626/0833 →
CHANGE OF NAME Recorded Feb 8, 2023
From: ORIG3N, INC.
To: SEAPORT DIAGNOSTICS, INC.
Reel/Frame 062682/0218 →
Continuity (3)
Provisional Application 62537257 · Jul 26, 2017
Provisional Application 62466361 · Mar 2, 2017
Related Publication 20200008917A1 · Jan 9, 2020